OKG Capital Research
Investment Thesis
OKG Capital is a small, specialist investor in early-stage medtech and life sciences companies. Its stated aim is to back high-impact companies with strong social value, particularly where there is a gap between clinical need and traditional venture capital priorities. The firm concentrates on chronic disease therapeutics and diagnostics, with oncology as the primary area. It describes close collaborations with pharmaceutical companies, clinical networks and charitable foundations, and says it makes itself available to founders and works alongside teams to help them through the challenges ahead.
Sector Focus
Active projects named on the firm's site span a wide band of healthcare innovation:
- Preclinical and clinical-stage drug discovery for solid tumor oncology
- CNS drug development for epilepsy and neurodegenerative diseases
- Oncology target discovery platforms
- Advanced imaging for cancer diagnosis
- Proteomic molecular diagnostics
- Antimicrobial resistance diagnostics
- Remote patient monitoring for acute oncology
The mix leans toward diagnostics and medical devices alongside therapeutics, which is consistent with the founding partner's medtech background.
Stage Focus
The firm describes itself as an investor in early-stage companies. Portfolio entries include university spinouts and clinical-stage companies. No explicit stage ladder is published, so stage preferences are inferred from third-party descriptions (early-stage medtech and life sciences).
Check Size
No check size or fund size is published on the website. A third-party tracker lists one tracked deal of about $1.7M. Check size and AUM are left unset.
Lead Tendency
Unknown. The 52North financing in December 2024, a roughly $6M round announced with a UK-US hospital venture partnership, names OKG Capital's Managing Partner in the press release, which suggests an active participant, but the lead investor is not established from the sources reviewed.
Recent Activity
The clearest recent public event is 52North Health's roughly $6M financing announced in December 2024, with OKG Capital involved. The website lists twelve portfolio logos and no news section, so recent activity is thinly documented.
Portfolio Highlights
The portfolio section links to iQure, 52 North Health, iFAST, Epion Therapeutics, Deeplook Medical, Pace Healthcare Capital, Oxford Cancer Analytics (OXcan), Hylid Diagnostics, Ymmunobio, 4D Lifetec, Lumedica and InSoma Bio. These are almost all oncology, diagnostics and medical device companies. No exits are listed.
Team
- Karim Galzahr, Managing Partner: 30 years in finance, including M&A, asset management, corporate development and strategic advisory across technology and medtech. Advisor and non-executive director to early-stage companies on finance, strategic partnering, investor relations, hiring and commercial deployment. Acting director at several private and public companies.
- Ines Galzahr: Corporate financial development in telecoms and technology, with senior M&A and strategic partnering responsibility. Trained economist with an interest in medical statistics. Responsible for financial analysis and capital raising dynamics for portfolio companies.
- Sol Jordan: Chemical engineer with oil and gas experience in process design, project management and ISO certification.
- Gabor Zichy: Industrial designer with a mechanical engineering background, experienced in consumer device design and manufacture. Co-founder of a robotics company and a design engineering consultancy.
Decision Process
Not published. The firm is a small team with a founder-led partner, so decisions are likely concentrated in the Managing Partner. This is an inference and is not recorded as a structured field.
Founder Preferences
Founders working on problems with clear clinical need and social value, especially in oncology and chronic disease, who value hands-on support on finance, strategic partnering, investor relations and commercial deployment. Pharma, clinical network and foundation relationships are a stated advantage.
Geographic Focus
Not stated on the site. Portfolio companies are linked to the UK (Oxford Cancer Analytics, 52North in the Cambridge ecosystem) and other European and US-linked ventures. Geographic preferences are left unset.
Gaps
No fund size, check size, location, stage ladder, lead tendency or decision process is published. Four portfolio logos (iFAST, Deeplook Medical, Lumedica, InSoma Bio) carry no readable image caption and were not added to the structured portfolio list.